fiercedrugdevforum.com

fiercepharma.com

Pharma | FiercePharma

http://www.fiercepharma.com/tags/industry-voices

Skip to main content. Main navigation - Mobile. Mylan CEO summoned by senators for 'urgent briefing' on EpiPen. Lundbeck's U.S. sales skyrocket on Abilify, Brintellix growth. Patent schemes, hostage government payers driving U.S. drug spending. Turing exec claims she was sexually assaulted by company co-founder. All the skinny on Mylan and EpiPen? We've gathered it right here. Is Pfizer buying AZ's antibiotics to beef up for a split? Aug 24, 2016 7:58am. By Beth Snyder Bulik. Aug 24, 2016 6:22am. India’s...

fiercepharma.com

Pharma's top 10 M&A deals of 2014's first half | FiercePharma

http://www.fiercepharma.com/special-reports/pharmas-top-10-ma-deals-2014s-first-half

Skip to main content. Main navigation - Mobile. Pharma's top 10 M&A deals of 2014's first half. Mergers and acquisitions have been non-stop this year, with lots of deals done, and some doozies that were unable to cross the finish line. Here we look at what's happened in the first half of the year; we will round out the entire year's activity in another report early next year. And it was the deal that didn't get done that may have had the biggest influence on the government finally clamping down. That...

fiercebiotech.com

Report: Icahn to launch bid for Genzyme control | FierceBiotech

http://www.fiercebiotech.com/story/report-icahn-launch-bid-genzyme-control/2010-02-22

Skip to main content. Main navigation - Mobile. Report: Icahn to launch bid for Genzyme control. Feb 22, 2010 8:19am. S source, activist investor Carl Icahn is launching a battle for control of Genzyme. Smelling blood in the water, Icahn has notified Genzyme that he will ask shareholders to appoint himself and three other directors of his choice to the company's board, according to. Adam Feuerstein. "Our actions demonstrate that we are open and responsive to shareholder input, and we welcome a constr...

fiercebiotech.com

Carfilzomib - 10 promising late-stage cancer drugs | FierceBiotech

http://www.fiercebiotech.com/special-reports/10-promising-late-stage-cancer-drugs/carfilzomib-10-promising-late-stage-cancer-drug

Skip to main content. Main navigation - Mobile. Carfilzomib - 10 promising late-stage cancer drugs. While Onyx Pharmaceuticals ($ONXX) has an approved kidney and liver cancer drug in Nexavar (sorafenib), much of the company's future value growth seems to be tied to its late-stage proteasome inhibitor carfilzomib. Onyx expects to complete submission of its application for FDA approval of the drug by mid-2011. Book traversal links for Carfilzomib - 10 promising late-stage cancer drugs. Aug 18, 2016.

fiercepharma.com

INCORRECT: Acorda deals MS med direct to patients | FiercePharma

http://www.fiercepharma.com/story/acorda-deals-ms-med-direct-patients/2010-03-29

Skip to main content. Main navigation - Mobile. INCORRECT: Acorda deals MS med direct to patients. Mar 29, 2010 10:24am. Article this piece was based on, Acorda has informed FiercePharma that the company is not selling directly to patients after all, but through specialty pharmacies. It's the sort of approach that makes us scratch our heads: Why don't more drugmakers develop an in-house ordering-and-fulfillment service- or contract out those functions- and reap more cash per every prescription filled?

fiercepharma.com

GSK sinks Advair prices to fend off Cipla copycat in India | FiercePharma

http://www.fiercepharma.com/story/gsk-sinks-advair-prices-fend-cipla-copycat-india/2015-08-03

Skip to main content. Main navigation - Mobile. GSK sinks Advair prices to fend off Cipla copycat in India. Aug 3, 2015 11:20am. GlaxoSmithKline ($GSK) isn't just going to sit back and let Cipla's generic stomp all over asthma blockbuster Advair- known as Seretide outside the U.S.- in India. It's turning to a strategy it's used elsewhere to help its aging med compete, and that's price-cutting. Meanwhile, even with the discount, Glaxo has a lot of ground to make up in India. Cipla boasts a 65% piece o...

fiercepharma.com

Integrating Cephalon, Teva eyes up to 1,500 job cuts | FiercePharma

http://www.fiercepharma.com/story/integrating-cephalon-teva-eyes-1500-job-cuts/2011-11-08

Skip to main content. Main navigation - Mobile. Integrating Cephalon, Teva eyes up to 1,500 job cuts. Nov 8, 2011 11:44am. Hard on the heels of its merger with Cephalon, Teva Pharmaceutical Industries ($TEVA) is sharpening its jobs axe. Israeli news sources report anywhere from 1,000 to 1,500 cuts, with most of the layoffs in Europe and the U.S., and many concentrated in Cephalon's generics business. One focus of cuts will be Mepha, the Swiss generics maker Cephalon bought last year,. Some other clues as...

fiercebiotech.com

Merck dumps Parkinson's program at Addex Pharma | FierceBiotech

http://www.fiercebiotech.com/story/merck-dumps-parkinsons-program-addex-pharma/2011-09-02

Skip to main content. Main navigation - Mobile. Merck dumps Parkinson's program at Addex Pharma. Sep 2, 2011 1:03pm. Merck has dealt some bad news to Swiss developer Addex Pharmaceuticals ($ADXN). The drug giant ($MRK), which has been culling R&D projects as it prioritizes its pipeline, has handed back to Addex rights to an mGluR4 positive allosteric modulator (PAM) program the companies had been working on for Parkinson's disease. At the start of the Merck deal in 2007, Addex grabbed $3 million upfront ...

fiercebiotech.com

Eli Lilly sets out to rewrite the R&D playbook | FierceBiotech

http://www.fiercebiotech.com/story/eli-lilly-sets-out-rewrite-r-d-playbook/2010-01-05

Skip to main content. Main navigation - Mobile. Eli Lilly sets out to rewrite the R&D playbook. Jan 5, 2010 10:19am. The days of giant R&D organizations orchestrating every step in the development of new drugs have ended. And you need only look at today's. For another telling example of the trend toward outsourcing and partnering. Chutes and Ladders: Google's Calico snags Daphne Koller from Coursera. Aug 19, 2016. UPDATED: Regeneron/Sanofi team hustling to the FDA with stellar PhIII dupilumab data.

fiercebiotech.com

Scientific insights into brain chemistry trigger drug trials for Down syndrome | FierceBiotech

http://www.fiercebiotech.com/story/scientific-insights-brain-chemistry-trigger-drug-trials-down-syndrome/2014-03-03

Skip to main content. Main navigation - Mobile. Scientific insights into brain chemistry trigger drug trials for Down syndrome. Mar 3, 2014 9:40am. Luca Santarelli, Roche's head of neuroscience. And a small biotech inspired by the work of Stanford University investigator Craig Garner is taking the same approach in the clinic with a drug dubbed BTD-001. It was shocking how well it worked.". In an email. "The trial will recruit 180 individuals with Down syndrome aged 12-30 across 10 countries. Our ...RG166...